MAGEA6

Summary

MAGEA6 (MAGE family member A6, HGNC:6804) is a protein-coding gene on chromosome Xq28, encoding Melanoma-associated antigen 6 (P43360). Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy.

This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 4105 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_005363

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6804
Approved symbol	MAGEA6
Name	MAGE family member A6
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	CT1.6, MAGE3B, MAGE-3b
Ensembl gene	ENSG00000197172
Ensembl biotype	protein_coding
OMIM	300176
Entrez	4105

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000329342, ENST00000412733, ENST00000457643, ENST00000616035, ENST00000923265

RefSeq mRNA: 2 — MANE Select: NM_005363 NM_005363, NM_175868

CCDS: CCDS76050

Canonical transcript exons

ENST00000329342 — 3 exons

Exon	Start	End
ENSE00001691201	152769654	152769689
ENSE00001753927	152767796	152767861
ENSE00001853660	152766136	152767715

Expression profiles

Bgee: expression breadth broad, 31 present calls, max score 87.79.

Top tissues by expression

119 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.79	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.10	gold quality
right testis	UBERON:0004534	72.99	gold quality
testis	UBERON:0000473	71.76	gold quality
left testis	UBERON:0004533	70.68	gold quality
placenta	UBERON:0001987	43.25	silver quality
bone marrow cell	CL:0002092	37.98	gold quality
sural nerve	UBERON:0015488	37.24	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
smooth muscle tissue	UBERON:0001135	34.00	gold quality
muscle tissue	UBERON:0002385	33.54	gold quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
bone marrow	UBERON:0002371	32.67	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
liver	UBERON:0002107	31.33	gold quality
blood	UBERON:0000178	30.65	gold quality
muscle of leg	UBERON:0001383	29.88	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
right coronary artery	UBERON:0001625	29.62	silver quality
gastrocnemius	UBERON:0001388	29.31	gold quality
urinary bladder	UBERON:0001255	29.08	gold quality
prefrontal cortex	UBERON:0000451	29.04	gold quality
right lobe of liver	UBERON:0001114	28.88	gold quality
heart left ventricle	UBERON:0002084	28.78	gold quality
cortex of kidney	UBERON:0001225	28.24	gold quality
endocervix	UBERON:0000458	28.16	gold quality
duodenum	UBERON:0002114	28.14	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-11	yes	89.79
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting MAGEA6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-216A-5P	99.50	68.02	1288
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-31-5P	98.58	68.35	1239
HSA-MIR-12120	98.05	68.44	1768
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-5586-3P	95.51	67.00	805
HSA-MIR-550B-3P	95.43	67.73	599
HSA-MIR-4301	95.00	65.22	554

Literature-anchored findings (GeneRIF, showing 17)

• Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. (PMID:12208877)
• MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma (PMID:12631591)
• Multiple simultaneous detection of MAGE-A [subtypes] more specific and sensitive than detection of single MAGE-A antigen for the diagnostic and prognostic evaluation of oral squamous cell carcinoma (PMID:18197853)
• Report MAGEA1-A6 expression in sputum suggests presence of lung cancer cells or precancerous cells. (PMID:22134685)
• To identify novel CTL epitopes from MAGE-A6 and MAGE-A12 antigens. (PMID:22707303)
• MAGEA3/6 positivity was associated with significantly better disease-free survival. (PMID:25564441)
• Study describes a widespread mechanism to suppress AMPK through its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 are highly similar proteins normally expressed only in the male germline but frequently re-activated in human cancers. (PMID:25679763)
• MageA6 and MageA11 form a protein complex resulting in the stabilization of MageA11 and consequently the enhancement of androgen receptor activity. (PMID:28542476)
• MAGEA6 promotes glioma cell survival possibly via targeting AMPKalpha1. (PMID:29024810)
• MAGEA6 knockdown by targeted-shRNA induced AMPK stabilization and activation, which led to mTOR complex 1 (mTORC1) in-activation and RCC cell death/apoptosis. (PMID:29448247)
• Data indicate that miR-1273g represses melanoma antigen family A 3/melanoma antigen family A 6 (MAGEA3/6 )expression in colorectal cancer (CRC) cells and tissues, which may suggest a cancer-specific therapeutic. (PMID:30056111)
• data indicate that the activation of CT-GABRA3 is correlated with that of MAGEA6. Therefore, MAGEA6 is linked with CT-GABRA3 through a bidirectional promoter. (PMID:31593956)
• High MAGEA6 expression is associated with recurrence in Gastric Cancer. (PMID:31704814)
• Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling. (PMID:31727877)
• Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. (PMID:32270762)
• Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer. (PMID:35022469)
• Knockdown of MAGE-A6 enhanced the irradiation sensitivity of non-small cell lung cancer cells by activating the AMPK pathway. (PMID:35285568)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	ndnl2	ENSDARG00000058212
drosophila_melanogaster	MAGE	FBGN0037481

Paralogs (37): MAGEC2 (ENSG00000046774), TRO (ENSG00000067445), MAGEB2 (ENSG00000099399), MAGED2 (ENSG00000102316), MAGEB4 (ENSG00000120289), MAGEA9 (ENSG00000123584), MAGEA10 (ENSG00000124260), MAGEA4 (ENSG00000147381), MAGED4 (ENSG00000154545), MAGEC1 (ENSG00000155495), MAGEA8 (ENSG00000156009), MAGEC3 (ENSG00000165509), MAGEB6 (ENSG00000176746), MAGEB18 (ENSG00000176774), MAGEF1 (ENSG00000177383), MAGEB10 (ENSG00000177689), MAGED1 (ENSG00000179222), NDN (ENSG00000182636), MAGEB17 (ENSG00000182798), MAGEA2B (ENSG00000183305), NSMCE3 (ENSG00000185115), MAGEA11 (ENSG00000185247), MAGEE2 (ENSG00000186675), MAGED4B (ENSG00000187243), MAGEH1 (ENSG00000187601), MAGEB5 (ENSG00000188408), MAGEB16 (ENSG00000189023), MAGEA1 (ENSG00000198681), MAGEB3 (ENSG00000198798), MAGEE1 (ENSG00000198934), MAGEA12 (ENSG00000213401), MAGEB1 (ENSG00000214107), MAGEA3 (ENSG00000221867), MAGEB6B (ENSG00000232030), MAGEL2 (ENSG00000254585), MAGEA9B (ENSG00000267978), MAGEA2 (ENSG00000268606)

Protein

Protein identifiers

Melanoma-associated antigen 6 — P43360 (reviewed: P43360)

Alternative names: Cancer/testis antigen 1.6, MAGE-6 antigen, MAGE3B antigen

All UniProt accessions (3): E7ETG4, E7EUF2, P43360

UniProt curated annotations — full annotation on UniProt →

Function. Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines.

Subunit / interactions. Interacts with TRIM28.

Tissue specificity. Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes.

Post-translational modifications. Ubiquitinated by the DCX(DCAF12) complex specifically recognizes the diglutamate (Glu-Glu) at the C-terminus, leading to its degradation.

RefSeq proteins (2): NP_005354, NP_787064 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002190	MHD_dom	Domain
IPR021072	MAGE_N	Domain
IPR037445	MAGE	Family
IPR041898	MAGE_WH1	Homologous_superfamily
IPR041899	MAGE_WH2	Homologous_superfamily

Pfam: PF01454, PF12440

UniProt features (7 total): compositionally biased region 3, chain 1, domain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P43360-F1	72.60	0.46

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 50 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_REGULATION_OF_AUTOPHAGY, HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_UP, HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_UP, GOBP_NEGATIVE_REGULATION_OF_AUTOPHAGY, GOBP_REGULATION_OF_CATABOLIC_PROCESS, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP, HAMAI_APOPTOSIS_VIA_TRAIL_DN, GOBP_NEGATIVE_REGULATION_OF_CATABOLIC_PROCESS, GOMF_HISTONE_DEACETYLASE_BINDING, ALONSO_METASTASIS_NEURAL_UP, HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_DN, chrXq28

GO Biological Process (2): negative regulation of transcription by RNA polymerase II (GO:0000122), negative regulation of autophagy (GO:0010507)

GO Molecular Function (2): histone deacetylase binding (GO:0042826), protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
autophagy	1
negative regulation of catabolic process	1
regulation of autophagy	1
enzyme binding	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

398 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAGEA6	CTAG2	O75638	825
MAGEA6	CTAG1A	P78358	786
MAGEA6	CSAG1	Q6PB30	636
MAGEA6	TRIM28	Q13263	622
MAGEA6	ARHGAP44	Q17R89	472
MAGEA6	NPAS4	Q8IUM7	470
MAGEA6	A0A1W2PQG5	A0A1W2PQG5	445
MAGEA6	ANAPC4	Q9UJX5	438
MAGEA6	CDC26	Q8NHZ8	437
MAGEA6	ANAPC7	Q9UJX3	437
MAGEA6	OR52E6	Q96RD3	431
MAGEA6	ANAPC1	Q9H1A4	422
MAGEA6	ANAPC11	Q9NYG5	419
MAGEA6	ZIM2	Q9NZV7	417
MAGEA6	GAGE4	P0DSO3	377

IntAct

376 interactions, top by confidence:

A	B	Type	Score
MAGEA6	ATPAF2	psi-mi:“MI:0915”(physical association)	0.810
ATPAF2	MAGEA6	psi-mi:“MI:0915”(physical association)	0.810
TULP3	MAGEA6	psi-mi:“MI:0915”(physical association)	0.780
STAMBPL1	MAGEA6	psi-mi:“MI:0915”(physical association)	0.780
MAGEA6	GFOD1	psi-mi:“MI:0915”(physical association)	0.780
MAGEA6	TULP3	psi-mi:“MI:0915”(physical association)	0.780
MAGEA6	STAMBPL1	psi-mi:“MI:0915”(physical association)	0.780
NCK2	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
RPL37A	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
MAGEA6	KLHL38	psi-mi:“MI:0915”(physical association)	0.720
MORN3	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
MAGEA6	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
MIPOL1	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
LIN37	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
MAGEA6	BCL7B	psi-mi:“MI:0915”(physical association)	0.720
MAGEA6	RASSF4	psi-mi:“MI:0915”(physical association)	0.720
SH2D4A	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
LSM2	MAGEA6	psi-mi:“MI:0915”(physical association)	0.720
MAGEA6	NCK2	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (120): MAGEA6 (Two-hybrid), PDE4D (Two-hybrid), RPL37A (Two-hybrid), STX5 (Two-hybrid), TULP3 (Two-hybrid), NCK2 (Two-hybrid), SNX4 (Two-hybrid), BCL7B (Two-hybrid), ATP6V1G1 (Two-hybrid), AKAP9 (Two-hybrid), TXNDC9 (Two-hybrid), BET1 (Two-hybrid), EXOC5 (Two-hybrid), ACOT7 (Two-hybrid), FRMPD1 (Two-hybrid)

ESM2 similar proteins: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A8MXT2, B2KFW1, O15479, O15480, O15481, O15553, P0C6Y7, P10073, P17040, P25233, P43355, P43356, P43357, P43358, P43360, P43362, P43363, P43364, P43366, Q13342, Q16666, Q4R998, Q5PPP4, Q5RD14, Q6AY37, Q6PCZ4, Q8BQR7, Q8IWY8, Q8IX06, Q8N660, Q8N7X4, Q8TD90, Q96DU7, Q96LZ2, Q96M61, Q99608

Diamond homologs: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A6NCF6, A6QLI5, A8MXT2, O15479, O15480, O15481, O60732, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q12816, Q4R998, Q5PPP4, Q5RFC2, Q6AY37, Q6ITT4, Q6PCZ4, Q8BQR7, Q8N7X4, Q8TD90, Q8TD91, Q96JG8, Q96LZ2, Q96M61, Q96MG7, Q99608, Q9BE18

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
DCAF12	“down-regulates quantity by destabilization”	MAGEA6	binding
Cullin4-RBX1-DDB1	“down-regulates quantity by destabilization”	MAGEA6	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

555 predictions. Top by Δscore:

Variant	Effect	Δscore
X:152767790:A:AC	donor_gain	1.0000
X:152767791:C:CC	donor_gain	1.0000
X:152767794:A:AC	donor_gain	1.0000
X:152767795:C:CC	donor_gain	1.0000
X:152767795:CAG:C	donor_gain	1.0000
X:152767795:CAGAT:C	donor_gain	1.0000
X:152769651:TA:T	donor_loss	1.0000
X:152769653:C:CT	donor_loss	1.0000
X:152767711:CTGGC:C	acceptor_gain	0.9900
X:152767713:GGCCT:G	acceptor_loss	0.9900
X:152767714:GCCTG:G	acceptor_loss	0.9900
X:152767716:C:CC	acceptor_gain	0.9900
X:152767717:T:A	acceptor_loss	0.9900
X:152767788:TTAC:T	donor_loss	0.9900
X:152767789:TACT:T	donor_loss	0.9900
X:152767790:ACTT:A	donor_loss	0.9900
X:152767791:CTTA:C	donor_gain	0.9900
X:152767792:TTA:T	donor_loss	0.9900
X:152767793:T:TC	donor_loss	0.9900
X:152767794:A:T	donor_loss	0.9900
X:152767795:CA:C	donor_gain	0.9900
X:152767795:CAGA:C	donor_gain	0.9900
X:152769652:A:AC	donor_gain	0.9900
X:152769653:C:CC	donor_gain	0.9900
X:152769653:CCTTG:C	donor_gain	0.9900
X:152769657:G:A	donor_gain	0.9900
X:152767860:ACCT:A	acceptor_loss	0.9800
X:152767862:C:CC	acceptor_gain	0.9800
X:152767863:T:C	acceptor_loss	0.9800
X:152767713:GGC:G	acceptor_gain	0.9700

AlphaMissense

2052 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:152767165:A:C	F162L	0.948
X:152767165:A:T	F162L	0.948
X:152767167:A:G	F162L	0.948
X:152766839:A:G	F271S	0.942
X:152766838:G:C	F271L	0.928
X:152766838:G:T	F271L	0.928
X:152766840:A:G	F271L	0.928
X:152766834:A:G	W273R	0.927
X:152766834:A:T	W273R	0.927
X:152766832:C:A	W273C	0.914
X:152766832:C:G	W273C	0.914
X:152766831:C:G	G274R	0.894
X:152766875:C:G	R259P	0.891
X:152767282:C:A	K123N	0.873
X:152767282:C:G	K123N	0.873
X:152767247:A:G	M135T	0.869
X:152766884:A:G	L256P	0.864
X:152767163:C:A	G163V	0.864
X:152766830:C:T	G274D	0.851
X:152767210:A:C	F147L	0.850
X:152767210:A:T	F147L	0.850
X:152767212:A:G	F147L	0.850
X:152766823:C:A	R276S	0.845
X:152766823:C:G	R276S	0.845
X:152766839:A:C	F271C	0.845
X:152767178:A:G	L158S	0.838
X:152766884:A:T	L256Q	0.837
X:152766811:T:A	E280D	0.829
X:152766811:T:G	E280D	0.829
X:152766833:C:G	W273S	0.828

dbSNP variants (sampled 300 via entrez): RS1047232 (X:152766387 A>C,G), RS1047234 (X:152766383 C>A,T), RS1157341385 (X:152771059 A>G), RS1157579855 (X:152769961 C>T), RS1157617735 (X:152767683 T>C), RS1157749045 (X:152766180 C>T), RS1159499064 (X:152770479 G>A), RS1159734005 (X:152768379 C>G), RS1160675613 (X:152770143 C>T), RS1161428356 (X:152770380 T>C), RS1161533488 (X:152771152 C>T), RS1161698114 (X:152769976 G>A), RS1161774599 (X:152768032 G>A), RS1161791731 (X:152766519 CAA>C,CAAA), RS1161914393 (X:152767808 T>C)

Disease associations

OMIM: gene MIM:300176 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST011353_5	Serum alkaline phosphatase levels	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Decitabine	affects expression	2
Mitomycin	affects response to substance, affects binding, decreases expression, increases response to substance	2
butyraldehyde	increases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Cisplatin	affects binding, decreases expression, increases response to substance	1
Etoposide	affects response to substance	1
Fluorouracil	decreases expression, affects response to substance	1
Gallic Acid	increases expression	1
Methotrexate	affects response to substance	1
Mitoxantrone	affects response to substance	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1WC	Abcam HeLa MAGEA6 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.